Kerri-Ann Millar

Kerri-Ann Millar

Chief Financial OfficeratCue Biopharma· In proxies 2022–2024

Pay in FY2024-10% from the year before · Cue Biopharma stock -58.7% the same year

Kerri-Ann Millar was paid $1.0M in FY2024 (Dec), down 10%. Cue Biopharma stock fell 58.7% that year.

Pay$100 in the stock at the end of FY21 → $10
Pay is from the Summary Compensation Table of each Cue Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cue BiopharmaPublic company · 4 yr
    • Chief Financial Officer2022 – Present · 4 yrStock in role -94%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?